Thanks for finding us at ESMO World Congress on Gastrointestinal Cancer

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases


​​​​​Thanks for finding us at ESMO World Congress on Gastrointestinal Cancer

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases

Highlights From Your Congress

View More
 
View More
View More

What’s Of Interest

View More
View MoreClose

Investigator Resources

View More
View More
View More
View More
View More

Commitment To Oncology

View More
View More

Scheduled Events

Abstract Title:

 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC
Lead Author: Dan Aderka
Sponsor: Pfizer
Type: Short Oral Presentation
Session Date and Time:
Friday, July 2, 2021 14:52 – 14:59

Abstract title:

ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer​​​​​​​
Lead Author: Eric Van Cutsem
Sponsor: Submitted by Pierre-Fabre
Type: Oral Presentation
Session Date and Time:
Friday, July 2, 2021 14:42-14:52

Abstract title:

Baseline characteristics of patients enrolled in the CAPSTAN study: a European retrospective study in BRAFV600E-mutant metastatic colorectal cancer patients (mCRC)
Lead Author: Professor Erika Martinelli
Sponsor: Submitted by Pierre-Fabre
Type: Poster Presentation

Opportunities To Connect


Connect with Pfizer
through our Contact Form

Medical Information​​​​​​​

Connect with Pfizer

Please fill out the form below. A member from the team will respond accordingly.

By providing your email address, you agree to receive an email response from Pfizer to your inquiry. Your email address will only be used to respond to your inquiry. The information you submit will be governed by our Privacy Policy.

All fields marked with an asterisk ( *) are required.

Thank you for
contacting Pfizer.

A team member will respond to your inquiry.

X

PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.